BMT CTN Protocol 1705 HR aGVHD AAT

BMT CTN 1705 - A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant

Below are protocol-related documents, which may be periodically updated.

             BMT CTN 1705 Co-Chair: Amin Alousi, MD

             BMT CTN 1705 Co-Chair: John Magenau, MD

             Protocol Coordinator: Theresa Pritchard, MS        

The BMT CTN is committed to including widespread transplant community participation in these trials. For information on how to apply to participate on this study, please contact the Protocol Coordinator Terry Pritchard at for details.